Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study

PURPOSE: Apatinib is an approved third-line treatment for metastatic gastric cancer in China and demonstrates good safety, tolerability, and efficacy in other advanced solid tumors. The aim of this prospective, single-arm, multicenter, phase 2 study was to assess the efficacy and safety of low-dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ning, Deng, Wenying, Zhang, Guifang, Du, Yali, Guo, Yanwei, Ma, Yijie, Wei, Chen, Bie, Liangyu, Zhang, Chi, Song, Tao, Luo, Suxia, Fang, Baijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443771/
https://www.ncbi.nlm.nih.gov/pubmed/34540697
http://dx.doi.org/10.3389/fonc.2021.728854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443771/
https://www.ncbi.nlm.nih.gov/pubmed/34540697
http://dx.doi.org/10.3389/fonc.2021.728854

Ejemplares similares